The DOI matches its Crossref record.
Review article: overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta‐analysis?
Abstract
Background: Controversies surrounding medical treatment in patients with unresectable hepatocellular carcinoma continue to persist. Aim: To perform a meta‐analysis of therapeutic modalities which had been evaluated in two or more randomized trials. Methods: Fifty‐two randomized trials were studied; only 30 were included. This overview identified seven therapeutic modalities which had been evaluated in two or more trials: adriamycin, 5‐fluorouracil, interferon, percutaneous ethanol injection, transarterial chemotherapy, the combination of lipiodol with transarterial chemotherapy, and tamoxifen. Results: Comparisons of survival between control groups showed substantial heterogeneity. There was no survival benefit at 1 year with adriamycin (mean difference 4%), 5‐fluorouracil (mean difference −3%), percutaneous ethanol injection (mean difference 6%) or transarterial chemotherapy (mean difference −2%). For interferon, the survival benefit was significant with the Der Simonian & Laird method (mean difference 9%, 95% CI = 1–18%, P = 0.04) but not with the Peto et al. method (2.4 mean odds ratio, 95% CI = O.9–6.8). The meta‐analysis of tamoxifen showed a borderline survival benefit (mean difference 25%, 95% CI = 0–49%, P = 0.05). However, in sensitivity analyses, the survival benefit of tamoxifen was no longer significant. Conclusions: No treatment has clearly proven efficacy in survival. 5‐Fluorouracil, adriamycin and transarterial chemotherapy were not associated with survival benefit at 1 year. The number of randomized controlled trials was insufficient to enable a conclusion to be reached for interferon and percutaneous ethanol injection. Controversy persists concerning tamoxifen efficacy. Interferon and tamoxifen require new randomized controlled trials on a larger population of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Cammà, C., Schepis, F., Orlando, A., Albanese, M., Shahied, L., Trevisani, F., Andreone, P., Craxì, A., & Cottone, M. (2002) · Radiology · doi:10.1148/radiol.2241011262 · Cited by 851
Zhu, A. X., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Muzikansky, A., Horgan, K., Sheehan, S., Hale, K. E., Enzinger, P. C., Bhargava, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9130 · Cited by 388
Metadata
- Authors
- Mathurin, Rixe, Carbonell, Bernard, Cluzel, Bellin, Khayat, Opolon, & Poynard
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1998-02
- Volume
- 12
- Issue
- 2
- Pages
- 111-126
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2124603900
- Cited by
- 164
- References
- 0
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review article: overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta‐analysis? https://app.cochat.ai/papers/10.1046/j.1365-2036.1998.00286.x
- The paper
- Mathurin, Rixe, Carbonell, Bernard, Cluzel, Bellin, Khayat, Opolon, & Poynard. (1998). Review article: overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta‐analysis? Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.1998.00286.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.